Drug Trial Radar · NCT01020383
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
Last checked: Nov 20, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
364
Actual
Start
Sep 2009
Primary completion
Apr 2011
Study completion Mar 2012
Sponsor
- Lead sponsor
- Ablynx, a Sanofi companyIndustry
- Sponsor type
- Industry
- First posted
- Nov 24, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients. Patients will receive standard treatment with acetylsalicylic acid (ASA) plus clopidogrel and heparin. Eligible patients will be randomly assigned to receive open-label study treatment with either ALX-0081 or ReoPro®. Patients will be stratified according to PCI type (elective or ad-hoc) and stent type (bare metal stent or drug eluting stent).
Conditions
- Unstable Angina
- Non ST Segment Elevation Myocardial Infarction (NSTEMI)
- Stable Angina (Associated With High Risk PCI)
Interventions
ALX-0081Drug
4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
ReoPro®Drug
0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of bleeding classified by the following criteria: TIMI major bleeding events, TIMI minor bleeding events, bleeding events requiring medical attention, defined as TIMI minimal bleeding eventsTime frame: 30 days
Locations
39 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
Graz, Austria
Site not named
Linz, Austria
Site not named
Vienna, Austria
Site not named
Aalst, Belgium
Site not named
Charleroi, Belgium
Site not named
Genk, Belgium
Site not named
Jette, Belgium
Site not named
Liège, Belgium
Site not named
Yvoir, Belgium
Site not named
Brno, Czechia
Site not named
Prague, Czechia
Site not named
Ústí nad Labem, Czechia
Site not named
Bad Nauheim, Germany
Site not named
Coburg, Germany
Site not named
Dortmund, Germany
Site not named
Hamburg, Germany
Site not named
Limburg, Germany
Site not named
Oldenburg, Germany
Site not named
Rostock, Germany
Site not named
Ashkelion, Israel
Site not named
Haifa, Israel
Site not named
Jerusalem, Israel
Site not named
Rehovot, Israel
Site not named
Tel HaShomer, Israel
Site not named
Bielsko-Biala, Poland
Site not named
Dąbrowa Górnicza, Poland
Site not named
Gdynia, Poland
Site not named
Grodzisk Mazowiecki, Poland
Site not named
Katowice, Poland
Site not named
Kędzierzyn, Poland
Site not named
Kościerzyna, Poland
Site not named
Krakow, Poland
Site not named
Lódz, Poland
Site not named
Poznan, Poland
Site not named
Torun, Poland
Site not named
Warsaw, Poland
Site not named
Wroclaw, Poland
Site not named
Lausanne, Switzerland
Site not named
Lugano, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.